MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Johns Hopkins Malaria Research Institute Releases Video Comparing Impact of COVID-19 to Malaria on the World
Johns Hopkins Highlights Impact of COVID-19 Compared to Malaria Through Educational Video
SANARIA INC. AND SEATTLE CHILDREN’S RESEARCH INSTITUTE ANNOUNCE COLLABORATION FOR DEVELOPMENT OF GENETICALLY ATTENUATED MALARIA VACCINES
Sanaria Inc. and Seattle Children’s Research Institute are proud to announce the signing of an agreement to collaborate on the development and commercialization of next generation PfSPZ vaccines attenuated by genetic engineering.
Sanaria welcomes Indonesian delegation to mark the restart of clinical trial activities
Sanaria was honored and delighted to welcome Colonel Nur Abdul Goni and Major Yogi Ertanto from the Pharmacy, Biomedics and Vaccines section of the Indonesian Institution of Armed Forces Health Centre (TNA) along with Prof. Amin Soebandrio, Dr. Rintis Noviyanti, and Prof. Kevin Baird of the Eijkman Institute for Molecular Biology (EIMB) in Jakarta.
SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES
In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
Sanaria Virtually Hosts National Student Leadership Conference
Sanaria's Dr. Peter Billingsley virtual hosts National Student Leadership Conference on June 15th and 28th.
Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine
Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine. Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.